Novelna is at the forefront of biotechnology and AI, transforming cancer diagnostics. Our mission is simple: ensure early disease detection is not a privilege, but a right for all. By advancing diagnostic technologies, we are committed to securing a healthier and brighter future globally
Early disease detection is pivotal for improved health outcomes. We are dedicated to enhancing accessibility, accuracy, and affordability in disease diagnostics, ensuring that everyone can have early insights into their health conditions.
At Novelna, we believe that financial success and creating a positive societal impact should coexist seamlessly. We are dedicated to realizing this balance through our pioneering methods in early cancer detection.
Our Technology: Taking Precision to New Heights
Our AI-enabled Proximity Extension Assay (PEA) technology seamlessly merges top-tier protein measurement with the latest in artificial intelligence. This integration is elevating the benchmark for biomarker discovery in cancers and other diseases, showcasing our commitment to advancing diagnostic precision and reliability.
